Companies Novo Nordisk A/S FollowCOPENHAGEN, Aug 10 (Reuters) - Novo Nordisk's (NOVOb.CO) limits on U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug will last into next year even as the Danish drugmaker spends billions boosting output, its CEO told Reuters on Thursday.
Earlier on Thursday, the company said it would continue to restrict U.S. supplies of starter doses of Wegovy as the company struggles to keep up with soaring demand.
Novo has denied this, but when asked about this on Thursday Jorgensen said there may be shortages.
The company expects to apply for regulatory approval for an expanded label indication in the U.S. and European Union later this year.
"It'll take some time before we get it on label," Jorgensen said.
Persons:
Lars Fruergaard Jorgensen, Thursday Jorgensen, Jim Vondruska, Jorgensen, " Jorgensen, Martin Lange, Nikolaj Skydsgaard, Jacob Gronholt, Josephine Mason, Jason Neely, Mark Potter
Organizations:
Novo Nordisk, COPENHAGEN, Reuters, REUTERS, Wegovy, Union, American Heart Association, Pedersen, Thomson
Locations:
Danish, Chicago , Illinois, U.S, Philadelphia, Copenhagen, London